Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698123 | 1.00 | OPRM1 (0.42) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL17303200 | 1.00 | OPRM1 (0.42) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL13698121 | 1.00 | OPRM1 (0.42) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL4194504 | 1.00 | OPRM1 (0.42) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL20459104 | 1.00 | OPRM1 (0.42) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL13698275 | 0.81 | OPRM1 (0.46) | OPRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4402453 | 0.81 | PTGS2 (0.36) | OPRM1 | |
| SCHEMBL8927314 | 0.81 | PTGS2 (0.36) | OPRM1 | |
| SCHEMBL13224854 | 0.81 | PTGS2 (0.36) | OPRM1 | |
| SCHEMBL13224856 | 0.81 | PTGS2 (0.36) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198198-A1 | CRYSTALLINE COMPOUNDS | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10800740-B2 | Crystalline compounds | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200039934-A1 | CRYSTALLINE COMPOUNDS | NEUROVANCE, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10280141-B2 | Crystalline compounds | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-2719384-B1 | Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180194726-A1 | CRYSTALLINE COMPOUNDS | AMRI SSCI, LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180194726-A1 | CRYSTALLINE COMPOUNDS | AMRI SSCI, LLC | 2018-07-12 | — | — | US | disclosed |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9205074-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2015-05-28 | — | — | US | disclosed |
| EP-2719384-A1 | Novel 1 -naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neurophychiatric disorders | Euthymic Bioscience, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | OPRM1 293/4885SLC6A4 261/4885SLC6A3 112/4885 |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | OPRM1 2248/4885SLC6A4 2230/4885SLC6A3 982/4885 |
| US-10280141-B2 | Crystalline compounds | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OPRM1 1951/4885SLC6A4 3216/4885SLC6A3 3390/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20200039934-A1 | CRYSTALLINE COMPOUNDS | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OPRM1 1951/4885SLC6A4 3216/4885SLC6A3 3390/4885 |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20180194726-A1 | CRYSTALLINE COMPOUNDS | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OPRM1 1951/4885SLC6A4 3216/4885SLC6A3 3390/4885 |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-10800740-B2 | Crystalline compounds | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OPRM1 1951/4885SLC6A4 3216/4885SLC6A3 3390/4885 |
| US-20210198198-A1 | CRYSTALLINE COMPOUNDS | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OPRM1 1951/4885SLC6A4 3216/4885SLC6A3 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.